Medication info
Jardiance Duo Tablets 12.5/500 mg (Empagliflozin, Metformin)

Jardiance Duo Tablets 12.5/500 mg (Empagliflozin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Empagliflozin›12.5mg / 1 tabletMetformin Hydrochloride›500mg / 1 tablet
Manufacturer / importer
Hana Pharmaceutical Co., Ltd.
Appearance
Light brownish-purple, biconvex oval film-coated tablet
Packaging
60 tablets/box [10 tablets/PTP x 6], 30 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle
Approval status
Active

MFDS item code 202302787 · Approved 2023.09.20 · Insurance code 657808060

Summary

Main use
Improves glycemic control in adults with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly Patients In patients 75 years of age or older, renal function and the risk of volume depletion should be taken into consideration.

Ingredients

Manufacturer
Hana Pharmaceutical Co., Ltd.

Efficacy & effects

Improves glycemic control in adults with type 2 diabetes mellitus

  • Difficulty in blood sugar control
  • type 2 diabetes
  • cardiovascular diseases
  • risk of cardiovascular events
View approved original text

This medication is used to help manage blood sugar in adults with type 2 diabetes who do not receive sufficient blood sugar control with diet and exercise alone. The combination of empagliflozin and metformin enhances blood sugar control and should be used cautiously in patients with cardiovascular disease. This drug helps improve blood sugar levels consistently, aiding in diabetes management.

How to take

Adult dose

The recommended dose of this medicine is 1 tablet twice daily. The dose should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: empagliflozin 25 mg and metformin 2000 mg. ⦁ For patients who cannot achieve adequate glycemic control with metformin alone or in combination with other medicines such as insulin, the recommended dose when taking this medicine is empagliflozin 5 mg twice daily (total daily dose 10 mg) and the patient's existing metformin dose. If empagliflozin 10 mg (total daily dose) is well tolerated and additional glycemic control is needed, the dose may be increased to empagliflozin 25 mg (total daily dose). ⦁ Patients switching to this medicine from combination therapy with empagliflozin (total daily dose 10 mg or 25 mg) and metformin should receive their existing doses of empagliflozin and metformin. When this medicine is administered concomitantly with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia (see Precautions for Use, 4. Adverse Reactions and 6. Interactions). This medicine should be taken with meals to reduce gastrointestinal adverse reactions associated with metformin. If you miss a dose of this medicine, take it as soon as you remember. However, do not take twice the dose at one time; if this occurs, skip the missed dose. Special Populations Patients with Renal Impairment No dose adjustment is necessary in patients with mild renal impairment. Because this medicine contains metformin, it may be used with dose adjustment in patients with an estimated glomerular filtration rate (eGFR) of 45-59 ml/min/1.73m2 or a CrCl of 45-59 ml/min who do not have other conditions that may increase the risk of lactic acidosis. Since the starting dose of metformin in these patients is 500 mg or 850 mg once daily, treatment should be initiated with the individual components, empagliflozin and metformin. The maximum daily dose of metformin hydrochloride that may be administered with this medicine is 1000 mg, which may be given as 500 mg twice daily. Renal function should be closely monitored every 3-6 months (see Precautions for Use, 3. Patients Requiring Caution, item 1)). If renal function declines to CrCl < 45 ml/min or eGFR < 45 ml/min/1.73m2, this medicine should be discontinued immediately (see Precautions for Use, 2. Patients Who Must Not Take This Medicine, item 2)). Elderly Patients In patients 75 years of age or older, renal function and the risk of volume depletion should be taken into consideration.

Precautions

This medication is used for diabetes treatment and contains two active ingredients: empagliflozin and metformin. While taking this medication, there is a risk of developing a rare side effect known as severe lactic acidosis. Lactic acidosis can lead to the accumulation of lactic acid in the body, which can be dangerous, especially in patients with impaired kidney function or those with acute infections, dehydration, or heart problems. Moreover, this medication may cause hypoglycemia (low blood sugar) when used with other diabetes treatments, so careful monitoring of blood sugar levels is necessary. Patients with moderate to severe renal impairment, acute kidney problems, severe liver dysfunction, acute heart failure, type 1 diabetes, or pregnant or breastfeeding women should not use this medication. Before and after the use of iodine contrast for examinations, the intake of this medication should be stopped and resumed only after ensuring normal kidney function. This drug can cause fluid loss, so special caution is required for patients at risk of dehydration or elderly patients undergoing hypertension treatment. During treatment, side effects such as symptoms of hypoglycemia, urinary tract infections, genital infections, increased urination, gastrointestinal disorders (nausea, vomiting, diarrhea, etc.) may occur; if any unusual symptoms arise, consult a doctor immediately. Vitamin B12 levels may decrease, so regular blood tests should be conducted to assess levels and supplementation may be needed. Alcohol consumption may increase the risk of lactic acidosis; hence, avoid excessive drinking during treatment. Elderly patients often have decreased renal function, so renal function tests should be conducted before use and monitored regularly, ensuring not to exceed maximum dosages. In preparation for surgery, the medication should be discontinued 48 hours prior and should be resumed only after a return to normal kidney function post-surgery. This medication is not for use in pregnant women or those who may become pregnant, as well as breastfeeding women. Regular blood tests and renal function checks are required during the treatment, with adjustments to dosage as directed by a physician based on symptoms. Finally, this medication should be kept out of the reach of children and stored in its original container.

Side effects

  • Hypoglycemia
  • urinary tract infection
  • genital infection
  • increased urination
  • ketoacidosis
  • lactic acidosis
  • decreased vitamin B12 absorption
  • reduced fluid volume
  • nausea
  • vomiting
Show 176 more
  • diarrhea
  • abdominal pain
  • loss of appetite
  • constipation
  • abnormal liver function tests
  • hepatitis
  • altered taste
  • pruritus
  • rash
  • urticaria
  • erythema
  • angioedema
  • dysuria
  • thirst
  • increased serum lipids
  • increased serum creatinine
  • decreased glomerular filtration rate
  • chronic gastritis
  • cerebral infarction
  • soft tissue infection
  • pneumonia
  • ankle fracture
  • epicondylitis
  • facial bone fracture
  • musculoskeletal pain
  • myocardial infarction
  • ketoacidosis
  • urosepsis
  • pyelonephritis
  • perineal necrosis
  • diarrhea
  • nausea
  • gastric ulcer
  • colitis
  • vomiting
  • ischemic colitis
  • colonic hemorrhage
  • appendiceal abscess
  • appendicitis
  • chronic otitis media
  • peritonsillar abscess
  • pulmonary tuberculosis
  • sepsis
  • subcutaneous abscess
  • tubo-ovarian abscess
  • vestibular neuritis
  • headache
  • sensory loss
  • positional dizziness
  • dizziness
  • memory impairment
  • drowsiness
  • CNS-origin vertigo
  • fatigue
  • peripheral edema
  • facial edema
  • fever
  • facial swelling
  • chills
  • strange sensations
  • edema
  • pain
  • pain at the puncture site
  • vascular stent stenosis
  • vascular stent thrombosis
  • chest pain
  • increased alanine aminotransferase
  • increased aspartate aminotransferase
  • weight gain
  • abnormal electrocardiogram
  • decreased hemoglobin
  • increased hemoglobin
  • positive Helicobacter test
  • positive urine red blood cells
  • ureteral calculi
  • acute kidney injury
  • chronic kidney disease
  • hematuria
  • overactive bladder
  • renal mass
  • urinary retention
  • urinary pain
  • abnormal urine
  • cervical inflammation
  • hyperglycemia
  • hyponatremia
  • dermal cyst
  • seborrheic dermatitis
  • atopic dermatitis
  • diabetic foot
  • nummular eczema
  • heat rash
  • sebaceous gland hyperplasia
  • lumbar spinal canal stenosis
  • myalgia
  • limb pain
  • musculoskeletal chest pain
  • arthralgia
  • cervical stenosis
  • fibromyalgia
  • flank pain
  • fracture pain
  • muscle weakness
  • osteoarthritis
  • osteoporosis
  • rotator cuff syndrome
  • astigmatism
  • cataract
  • allergic conjunctivitis
  • blurred vision
  • corneal abrasion
  • glaucoma
  • macular fibrosis
  • eye discomfort
  • conjunctival hyperemia
  • pathological myopia
  • retinal detachment
  • retinal lattice degeneration
  • retinal vein occlusion
  • traction retinal detachment
  • eyelid swelling
  • visual impairment
  • vitreous floaters
  • vitreous hemorrhage
  • nasal bleeding
  • asthma
  • exertional dyspnea
  • wet cough
  • allergic rhinitis
  • residual phlegm
  • cough
  • skin laceration
  • contusion
  • rib fracture
  • concussion
  • corneal abrasion
  • fall
  • hand fracture
  • iliotibial band syndrome
  • open globe injury
  • pelvic fracture
  • motor vehicle accident
  • splenic injury
  • sternum fracture
  • angina pectoris
  • palpitations
  • Prinzmetal angina
  • coronary artery disease
  • tachycardia
  • atherosclerosis
  • deep vein thrombosis
  • diabetic vascular complications
  • peripheral arterial occlusive disease
  • anxiety
  • depression
  • sleep disorders
  • acute cholecystitis
  • autoimmune hepatitis
  • cholelithiasis
  • hepatitis
  • otalgia
  • positional vertigo
  • vertigo
  • anemia
  • lymphadenopathy
  • hypothyroidism
  • thyroid nodules
  • constipation
  • dyspepsia
  • gastritis
  • gastrointestinal disorders
  • herpes zoster
  • insomnia
  • vulvar pruritus
  • genital pruritus
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air and moisture from entering. A storage temperature of 1 to 30 degrees Celsius at room temperature is recommended.

Appearance and packaging

Appearance

Light brownish-purple, biconvex oval film-coated tablet

Package unit

60 tablets/box [10 tablets/PTP x 6], 30 tablets/bottle, 10 tablets/box [10 tablets/PTP x 1], 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.